RedHill BioPharma Acquires Pancreatic Cancer Drug From RESprotect

August 14, 2014 | RedHill BioPharma, an emerging Israeli biopharmaceutical company focusing on the treatment of inflammatory and gastrointestinal diseases, has acquired an option for a Phase II pancreatic cancer drug RP101. RedHill acquired the cancer-treating drug from Dresden, Germany-based company RESprotect GmbH, a spin-off of the Fraunhofer Society. According to RedHIll, RP101 has completed Phase I and II clinical trials and has been granted the Orphan Drug designation for the treatment of pancreatic cancer by the United States Food & Drug Administration (FDA) and the European Medicines Agency (EMA).